Symbols / TBIO $0.06 +0.00% Telesis Bio, Inc.

Healthcare • Medical Devices • United States • PNK
TBIO Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Eric Esser
Exch · Country PNK · United States
Market Cap 97.67K
Enterprise Value 42.97M
Income -47.45M
Sales 17.03M
FCF (ttm) -10.21M
Book/sh -15.35
Cash/sh 2.54
Employees 39
Insider 10d —
IPO Jun 18, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.00
PEG —
P/S 0.01
P/B -0.00
P/C —
EV/EBITDA -1.50
EV/Sales 2.52
Quick Ratio 0.87
Current Ratio 1.23
Debt/Eq 420.52
LT Debt/Eq —
EPS (ttm) -30.42
EPS next Y -18.89
EPS Growth —
Revenue Growth -61.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-06-11
Earnings (prior) 2025-06-11
ROA -30.10%
ROE -178.99%
ROIC —
Gross Margin 46.87%
Oper. Margin -3.28%
Profit Margin -267.41%
Shs Outstand 1.78M
Shs Float 1.24M
Insider Own 2.36%
Instit Own 29.33%
Short Float 7.31%
Short Ratio 0.42
Short Interest 29.70K
52W High 0.88
vs 52W High -93.75%
52W Low 0.00
vs 52W Low 5,400.00%
Beta 2.50
Impl. Vol. —
Rel Volume 0.02
Avg Volume 152.00
Volume 3.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.06
Price $0.06
Change 0.00%
About

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It has license agreement with Regeneron Pharmaceuticals, Inc. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.06
Latest analyst target
3. DCF / Fair value
$-103.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.06
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-08-11 down Keybanc Overweight → Sector Weight —
News
RSS: Latest TBIO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-07-24 GOLUB STEVEN J Director — 8,390 $0.00 $0
2024-07-24 HLAVINKA SARAH E Director — 8,390 $0.00 $0
2024-07-24 WEISSMAN JAMES B. Director — 8,390 $0.00 $0
2024-07-24 KRUEGER TODD Director — 8,390 $0.00 $0
2024-07-24 HODGES MICHAEL R. Director — 8,390 $0.00 $0
2024-05-01 WITNEY FRANKLIN R. PH.D. Director — 95,106 — —
2024-05-01 TSINGOS CHRISTINE A Director — 83,861 — —
2024-05-01 NACHTSHEIM JAMI DOVER K Director — 81,049 — —
2024-05-01 HERREMA GREGORY J Director — 31,486 — —
2024-05-01 TUMOLO ANNETTE Director — 83,158 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Revenue
27.51
+0.27%
27.43
+148.44%
11.04
Operating Revenue
27.51
+0.27%
27.43
+148.44%
11.04
Cost Of Revenue
10.56
-10.82%
11.84
+75.56%
6.74
Reconciled Cost Of Revenue
10.56
-10.82%
11.84
+75.56%
6.74
Gross Profit
16.95
+8.69%
15.60
+262.76%
4.30
Operating Expense
52.10
-16.08%
62.08
+56.48%
39.67
Research And Development
17.50
-25.42%
23.46
+62.17%
14.47
Selling General And Administration
34.60
-10.40%
38.62
+53.21%
25.21
Selling And Marketing Expense
13.51
-18.04%
16.49
+50.47%
10.96
General And Administrative Expense
21.09
-4.70%
22.13
+55.32%
14.25
Other Gand A
21.09
-4.70%
22.13
+55.32%
14.25
Total Expenses
62.66
-15.23%
73.92
+59.25%
46.42
Operating Income
-35.15
+24.38%
-46.48
-31.41%
-35.37
Total Operating Income As Reported
-46.54
-0.12%
-46.48
-31.41%
-35.37
EBITDA
-40.49
+7.16%
-43.62
-21.15%
-36.00
Normalized EBITDA
-29.43
+31.38%
-42.90
-26.68%
-33.86
Reconciled Depreciation
4.10
+42.68%
2.88
+82.66%
1.57
EBIT
-44.59
+4.08%
-46.49
-23.73%
-37.58
Total Unusual Items
-11.06
-1437.97%
-0.72
+66.39%
-2.14
Total Unusual Items Excluding Goodwill
-11.06
-1437.97%
-0.72
+66.39%
-2.14
Special Income Charges
-11.39
-1466.57%
-0.73
-17.64%
-0.62
Other Special Charges
—
0.73
+17.64%
0.62
Impairment Of Capital Assets
11.39
0.00
—
Net Income
-47.72
+1.54%
-48.47
-24.42%
-38.96
Pretax Income
-47.70
+1.54%
-48.45
-24.40%
-38.94
Net Non Operating Interest Income Expense
-1.36
-11.91%
-1.22
+11.10%
-1.37
Interest Expense Non Operating
3.10
+58.82%
1.96
+42.80%
1.37
Net Interest Income
-1.36
-11.91%
-1.22
+11.10%
-1.37
Interest Expense
3.10
+58.82%
1.96
+42.80%
1.37
Interest Income Non Operating
1.74
+136.18%
0.74
—
Interest Income
1.74
+136.18%
0.74
—
Other Income Expense
-11.19
-1401.74%
-0.74
+66.15%
-2.20
Other Non Operating Income Expenses
-0.13
-400.00%
-0.03
+58.06%
-0.06
Gain On Sale Of Security
0.33
+4037.50%
0.01
+100.53%
-1.52
Tax Provision
0.02
+0.00%
0.02
+71.43%
0.01
Tax Rate For Calcs
0.00
+0.00%
0.00
-22.22%
0.00
Tax Effect Of Unusual Items
-2.32
-1437.97%
-0.15
+73.86%
-0.58
Net Income Including Noncontrolling Interests
-47.72
+1.54%
-48.47
-24.42%
-38.96
Net Income From Continuing Operation Net Minority Interest
-47.72
+1.54%
-48.47
-24.42%
-38.96
Net Income From Continuing And Discontinued Operation
-47.72
+1.54%
-48.47
-24.42%
-38.96
Net Income Continuous Operations
-47.72
+1.54%
-48.47
-24.42%
-38.96
Normalized Income
-38.99
+18.61%
-47.90
-28.09%
-37.40
Net Income Common Stockholders
-49.02
-1.14%
-48.47
-24.42%
-38.96
Diluted EPS
-29.52
+0.61%
-29.70
+22.90%
-38.52
Basic EPS
-29.52
+0.61%
-29.70
+22.90%
-38.52
Basic Average Shares
1.66
+1.31%
1.64
+61.69%
1.01
Diluted Average Shares
1.66
+1.31%
1.64
+61.69%
1.01
Diluted NI Availto Com Stockholders
-49.02
-1.14%
-48.47
-24.42%
-38.96
Preferred Stock Dividends
1.30
—
—
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
70.41
-13.46%
81.36
-30.02%
116.26
Current Assets
30.35
-44.91%
55.09
-40.88%
93.18
Cash Cash Equivalents And Short Term Investments
19.16
-56.04%
43.58
-47.37%
82.81
Cash And Cash Equivalents
1.57
-94.84%
30.42
-63.26%
82.81
Other Short Term Investments
17.59
+33.66%
13.16
0.00
Receivables
5.99
+2.29%
5.85
+59.65%
3.67
Accounts Receivable
5.99
+2.29%
5.85
+59.65%
3.67
Gross Accounts Receivable
7.27
+17.40%
6.19
+69.00%
3.67
Allowance For Doubtful Accounts Receivable
-1.29
-275.22%
-0.34
0.00
Inventory
4.03
+82.95%
2.20
-7.09%
2.37
Raw Materials
2.03
+94.06%
1.04
+8.52%
0.96
Work In Process
1.03
+59.35%
0.65
-27.79%
0.90
Finished Goods
0.97
+90.18%
0.51
-0.20%
0.51
Prepaid Assets
—
—
4.34
Restricted Cash
0.17
+0.00%
0.17
0.00
Other Current Assets
1.01
-69.34%
3.29
-24.33%
4.34
Total Non Current Assets
40.06
+52.49%
26.27
+13.86%
23.07
Net PPE
34.52
+305.12%
8.52
+48.53%
5.74
Gross PPE
37.99
+263.19%
10.46
+60.20%
6.53
Accumulated Depreciation
-3.47
-79.02%
-1.94
-144.64%
-0.79
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
9.86
+36.08%
7.24
+176.62%
2.62
Construction In Progress
0.59
-60.96%
1.50
-2.28%
1.54
Other Properties
27.22
+1539.76%
1.66
-27.22%
2.28
Leases
0.33
+472.41%
0.06
-38.95%
0.10
Goodwill And Other Intangible Assets
4.86
-70.99%
16.77
+0.25%
16.73
Goodwill
3.50
-76.51%
14.89
+3.88%
14.33
Other Intangible Assets
1.37
-27.36%
1.88
-21.49%
2.40
Other Non Current Assets
0.68
-31.09%
0.98
+61.08%
0.61
Total Liabilities Net Minority Interest
40.87
+17.46%
34.80
+36.60%
25.47
Current Liabilities
8.18
-39.37%
13.50
+38.68%
9.73
Payables And Accrued Expenses
5.93
-30.46%
8.53
+16.01%
7.35
Payables
3.28
+153.59%
1.29
-48.18%
2.50
Accounts Payable
3.28
+153.59%
1.29
-48.18%
2.50
Current Accrued Expenses
2.65
-63.40%
7.24
+49.05%
4.85
Current Debt And Capital Lease Obligation
1.82
+186.03%
0.64
-65.38%
1.84
Current Debt
—
—
0.60
Other Current Borrowings
—
—
0.60
Current Capital Lease Obligation
1.82
+186.03%
0.64
-48.50%
1.24
Current Deferred Liabilities
0.34
-91.46%
3.96
+1830.73%
0.20
Current Deferred Revenue
0.34
-91.46%
3.96
+1830.73%
0.20
Other Current Liabilities
0.09
-75.34%
0.37
+11.34%
0.34
Total Non Current Liabilities Net Minority Interest
32.69
+53.48%
21.30
+35.32%
15.74
Long Term Debt And Capital Lease Obligation
32.56
+56.60%
20.79
+34.28%
15.48
Long Term Debt
5.27
-73.18%
19.65
+39.47%
14.09
Long Term Capital Lease Obligation
27.29
+2291.67%
1.14
-18.15%
1.39
Non Current Deferred Liabilities
0.10
-33.10%
0.14
-5.33%
0.15
Non Current Deferred Revenue
0.10
-33.10%
0.14
-5.33%
0.15
Stockholders Equity
29.54
-36.57%
46.56
-48.71%
90.78
Common Stock Equity
0.24
-99.49%
46.56
-48.71%
90.78
Capital Stock
29.30
+586000.00%
0.01
+0.00%
0.01
Common Stock
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
29.30
0.00
0.00
Share Issued
1.67
+1.40%
1.65
+1.12%
1.63
Ordinary Shares Number
1.67
+1.40%
1.65
+1.12%
1.63
Additional Paid In Capital
161.70
+0.87%
160.30
+2.73%
156.05
Retained Earnings
-161.47
-41.96%
-113.74
-74.26%
-65.27
Gains Losses Not Affecting Retained Earnings
0.00
+100.00%
-0.00
0.00
Other Equity Adjustments
—
-0.00
—
Total Equity Gross Minority Interest
29.54
-36.57%
46.56
-48.71%
90.78
Total Capitalization
34.81
-47.43%
66.21
-36.86%
104.87
Working Capital
22.17
-46.71%
41.59
-50.16%
83.45
Invested Capital
5.51
-91.68%
66.21
-37.22%
105.47
Total Debt
34.38
+60.45%
21.43
+23.70%
17.32
Net Debt
3.70
—
—
Capital Lease Obligations
29.11
+1537.29%
1.78
-32.42%
2.63
Net Tangible Assets
24.67
-17.19%
29.80
-59.76%
74.06
Tangible Book Value
-4.63
-115.53%
29.80
-59.76%
74.06
Derivative Product Liabilities
0.04
-90.19%
0.37
+239.81%
0.11
Preferred Stock Equity
29.30
—
—
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-34.67
+10.46%
-38.72
-5.50%
-36.70
Cash Flow From Continuing Operating Activities
-34.67
+10.46%
-38.72
-5.50%
-36.70
Net Income From Continuing Operations
-47.72
+1.54%
-48.47
-24.42%
-38.96
Depreciation Amortization Depletion
4.10
+42.68%
2.88
+82.66%
1.57
Depreciation
3.59
+51.99%
2.36
+111.47%
1.12
Amortization Cash Flow
0.52
+0.00%
0.52
+12.45%
0.46
Depreciation And Amortization
4.10
+42.68%
2.88
+82.66%
1.57
Amortization Of Intangibles
0.52
+0.00%
0.52
+12.45%
0.46
Other Non Cash Items
0.77
+58.71%
0.48
+44.74%
0.33
Stock Based Compensation
3.96
+6.33%
3.73
+243.19%
1.09
Provisionand Write Offof Assets
1.20
+249.27%
0.34
—
Asset Impairment Charge
11.63
0.00
0.00
Operating Gains Losses
-0.20
-127.05%
0.72
-68.71%
2.30
Gain Loss On Investment Securities
-0.33
-4037.50%
-0.01
-100.48%
1.66
Gain Loss On Sale Of PPE
0.14
+6700.00%
0.00
—
Change In Working Capital
-7.77
-534.58%
1.79
+158.84%
-3.04
Change In Receivables
-1.33
+47.33%
-2.53
-244.08%
-0.73
Changes In Account Receivables
-1.33
+47.33%
-2.53
-244.08%
-0.73
Change In Inventory
-1.82
-1186.31%
0.17
+111.49%
-1.46
Change In Prepaid Assets
2.52
+268.18%
0.69
+117.49%
-3.92
Change In Payables And Accrued Expense
-3.29
-382.46%
1.16
-73.53%
4.39
Change In Other Working Capital
-3.67
-197.94%
3.74
+790.77%
-0.54
Change In Other Current Liabilities
-0.18
+87.60%
-1.44
-86.08%
-0.78
Investing Cash Flow
-5.74
+68.10%
-18.01
-19.73%
-15.04
Cash Flow From Continuing Investing Activities
-5.74
+68.10%
-18.01
-19.73%
-15.04
Net PPE Purchase And Sale
-1.96
+56.04%
-4.47
-140.99%
-1.85
Purchase Of PPE
-1.98
+55.68%
-4.47
-140.99%
-1.85
Sale Of PPE
0.02
0.00
—
Capital Expenditure
-1.98
+55.68%
-4.47
-140.99%
-1.85
Net Investment Purchase And Sale
-3.78
+70.89%
-12.98
0.00
Purchase Of Investment
-33.77
+56.38%
-77.43
0.00
Sale Of Investment
30.00
-53.46%
64.44
0.00
Net Business Purchase And Sale
0.00
+100.00%
-0.56
+95.78%
-13.19
Purchase Of Business
0.00
+100.00%
-0.56
+95.78%
-13.19
Financing Cash Flow
11.56
+156.43%
4.51
-96.28%
121.08
Cash Flow From Continuing Financing Activities
11.56
+156.43%
4.51
-96.28%
121.08
Net Issuance Payments Of Debt
-15.09
-422.34%
4.68
-52.18%
9.79
Issuance Of Debt
0.00
-100.00%
19.76
+32.87%
14.87
Repayment Of Debt
-15.09
-0.09%
-15.08
-196.77%
-5.08
Long Term Debt Issuance
0.00
-100.00%
19.76
+32.87%
14.87
Long Term Debt Payments
-15.09
-0.09%
-15.08
-196.77%
-5.08
Net Long Term Debt Issuance
-15.09
-422.34%
4.68
-52.18%
9.79
Net Common Stock Issuance
—
0.00
-100.00%
112.48
Proceeds From Stock Option Exercised
8.25
+1321.90%
0.58
+235.26%
0.17
Net Other Financing Charges
—
-0.75
+44.99%
-1.37
Changes In Cash
-28.85
+44.75%
-52.21
-175.30%
69.34
Beginning Cash Position
30.59
-63.05%
82.81
+515.06%
13.46
End Cash Position
1.75
-94.30%
30.59
-63.05%
82.81
Free Cash Flow
-36.65
+15.14%
-43.18
-12.01%
-38.55
Interest Paid Supplemental Data
2.23
+61.86%
1.38
+67.15%
0.82
Income Tax Paid Supplemental Data
0.02
0.00
—
Amortization Of Securities
-0.64
-259.22%
-0.18
0.00
Common Stock Issuance
—
0.00
-100.00%
112.48
Issuance Of Capital Stock
18.41
0.00
-100.00%
112.48
Net Preferred Stock Issuance
18.41
0.00
—
Other Cash Adjustment Inside Changein Cash
-0.00
0.00
—
Preferred Stock Issuance
18.41
0.00
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category